BR0307016A - ácidos 3-(imidazolil)-2-alcoxipropanóicos - Google Patents

ácidos 3-(imidazolil)-2-alcoxipropanóicos

Info

Publication number
BR0307016A
BR0307016A BR0307016-6A BR0307016A BR0307016A BR 0307016 A BR0307016 A BR 0307016A BR 0307016 A BR0307016 A BR 0307016A BR 0307016 A BR0307016 A BR 0307016A
Authority
BR
Brazil
Prior art keywords
imidazolyl
acids
alkyl
hydrogen
optionally substituted
Prior art date
Application number
BR0307016-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Charlotte Moira Norfo Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0307016A publication Critical patent/BR0307016A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0307016-6A 2002-01-22 2003-01-10 ácidos 3-(imidazolil)-2-alcoxipropanóicos BR0307016A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids
PCT/IB2003/000060 WO2003061652A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Publications (1)

Publication Number Publication Date
BR0307016A true BR0307016A (pt) 2004-11-03

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307016-6A BR0307016A (pt) 2002-01-22 2003-01-10 ácidos 3-(imidazolil)-2-alcoxipropanóicos

Country Status (24)

Country Link
EP (1) EP1467731A1 (zh)
JP (1) JP2005520811A (zh)
KR (1) KR20040077775A (zh)
CN (1) CN1620291A (zh)
AP (1) AP2004003084A0 (zh)
AR (1) AR038197A1 (zh)
BR (1) BR0307016A (zh)
CA (1) CA2472238A1 (zh)
EA (1) EA200400716A1 (zh)
EC (1) ECSP045200A (zh)
HR (1) HRP20040659A2 (zh)
IL (1) IL162677A0 (zh)
IS (1) IS7310A (zh)
MA (1) MA27167A1 (zh)
MX (1) MXPA04006573A (zh)
NO (1) NO20043457L (zh)
OA (1) OA12756A (zh)
PA (1) PA8563501A1 (zh)
PE (1) PE20030929A1 (zh)
PL (1) PL371487A1 (zh)
TN (1) TNSN04121A1 (zh)
TW (1) TW200302094A (zh)
UY (1) UY27615A1 (zh)
WO (1) WO2003061652A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
WO2006113247A1 (en) * 2005-04-18 2006-10-26 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
WO2010050525A1 (ja) 2008-10-29 2010-05-06 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
AU2009322342A1 (en) * 2008-12-05 2011-06-30 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
KR20130006620A (ko) * 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
RU2572814C2 (ru) 2010-03-18 2016-01-20 Дайити Санкио Компани, Лимитед ЦИКЛОАЛКИЛ-ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ ИМИДАЗОЛА, ОБЛАДАЮЩЕЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ TAFIa
RU2015156612A (ru) 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
WO2017170460A1 (ja) 2016-03-29 2017-10-05 第一三共株式会社 炎症性腸疾患治療剤
AU2018333913B2 (en) 2017-09-14 2022-11-17 Daiichi Sankyo Company, Limited Compound having cyclic structure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
BR0113289A (pt) * 2000-08-17 2003-06-17 Pfizer Imidazóis substituìdos como inibidores de tafia

Also Published As

Publication number Publication date
HRP20040659A2 (en) 2004-10-31
TNSN04121A1 (en) 2006-06-01
MXPA04006573A (es) 2004-10-04
CA2472238A1 (en) 2003-07-31
CN1620291A (zh) 2005-05-25
PL371487A1 (en) 2005-06-13
OA12756A (en) 2006-07-03
TW200302094A (en) 2003-08-01
IL162677A0 (en) 2005-11-20
PA8563501A1 (es) 2004-08-31
JP2005520811A (ja) 2005-07-14
AR038197A1 (es) 2005-01-05
AP2004003084A0 (en) 2004-09-30
WO2003061652A1 (en) 2003-07-31
EP1467731A1 (en) 2004-10-20
UY27615A1 (es) 2003-08-29
EA200400716A1 (ru) 2004-12-30
KR20040077775A (ko) 2004-09-06
NO20043457L (no) 2004-08-19
ECSP045200A (es) 2004-08-27
MA27167A1 (fr) 2005-01-03
PE20030929A1 (es) 2003-11-05
WO2003061652A8 (en) 2004-09-10
IS7310A (is) 2004-06-14

Similar Documents

Publication Publication Date Title
NO20020725D0 (no) Celleadhesjonsinhibitorer
NO20065178L (no) Tienopyridinderivater
ATE386043T1 (de) Metallocene und von ihnen abgeleitete katalysatorzusammensetzungen
NO20050065L (no) Kjemiske forbindelser
DE60213452D1 (de) Metallocene und verfahren zur herstellung von propylenpolymeren
IN2012DN00758A (zh)
EP1254895A4 (en) CYCLIC NITROGEN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR0307016A (pt) ácidos 3-(imidazolil)-2-alcoxipropanóicos
ATE497948T1 (de) Bicyclische verbindungen
MXPA04005940A (es) Acidos 3-(imidazolil)-2-aminopropanoicos.
DK1644389T3 (da) Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger
DE69915514D1 (de) Prenyltransferase-inhibitoren
ATE279476T1 (de) Silikonhaltige zusammensetzungen für die behandlung von wollematerialien
BR0317719A (pt) Derivados de fosforamida
ATE223414T1 (de) Prozess zur herstellung von zwischebprodukten für imidazodeazepinen
TR200002485T2 (tr) N-Sülfonil ve N-Sülfinil Fenilglisinamid
DE60013515D1 (de) 4-Arylpiperidinderivate zur Behandlung von Pruritus
BRPI0805173A2 (pt) monÈmeros funcionalizados e polìmeros elásticos funcionalizados feitos com eles
BR9714436A (pt) Processo para produção de derivados de imidazol
DOP2003000564A (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos
DE50206142D1 (de) Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen
ATE261962T1 (de) Benzonaphtyridin-1,8 derivate
TH40965A (th) ตัวเร่งปฏิกิริยาสำหรับโพลิเมอไรเซชันแอลฟา-โอเลฟินที่มีสารประกอบอะมิโนไซเลนที่ถูกแทนที่
ITMI20050893A1 (it) N-2-idrossialcanoil-n,n'-dialchiluree e procedimento per la loro preparazione

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4O, 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2047 DE 30/03/2010.